000952 Hubei Guangji Pharmaceutical
- 5.93
- -0.25-4.05%
Hubei Guangji Pharmaceutical News
Hubei Guangji Pharmaceutical (000952.SZ) subsidiary Guanghua Pharmaceutical intends to raise capital and introduce no less than two strategic investors.
Hubei Guangji Pharmaceutical (000952.SZ) announced that its wholly-owned subsidiary Hubei Guanghua Pharmaceutical Co., Ltd. ("Guanghua...
Hubei Guangji Pharmaceutical (000952.SZ) has received the approval notification for the supplemental application of Pharmaceutical Acyclovir hydrochloride tablets.
Hubei Guangji Pharmaceutical (000952.SZ) announced that recently, the company received the approval issued by the National Medical Products Administration for the hydrochloride...
Hubei Guangji Pharmaceutical (000952.SZ): Guanghua Pharmaceutical intends to pre-list and introduce strategic investors through capital increase and share expansion.
On November 15, Gelonghui reported that Hubei Guangji Pharmaceutical (000952.SZ) announced that its wholly-owned subsidiary Hubei Guanghua Pharmaceutical Co., Ltd. (hereinafter referred to as "Guanghua Pharmaceutical") intends to pre-list on the Shanghai United Assets and Equity Exchange to introduce strategic investors through capital increase. In order to effectively utilize asset resources and realize asset value, the wholly-owned subsidiary Guanghua Pharmaceutical plans to pre-list on the Shanghai United Assets and Equity Exchange to introduce strategic investors through capital increase. This pre-listing is only for information disclosure purposes, aimed at soliciting interested parties and does not constitute a trading action.
Guangji Pharmaceutical: Report for the third quarter of 2024
hubei guangji pharmaceutical (000952.SZ): a net loss of 0.159 billion yuan in the first three quarters.
October 30th, Guangji Pharmaceutical (000952.SZ) released its third quarter report for 2024, achieving revenue of 0.462 billion yuan in the first three quarters, a decrease of 11.54% year-on-year; net income attributable to shareholders of the listed company was -0.159 billion yuan; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was -0.172 billion yuan; basic earnings per share was -0.4498 yuan.
hubei guangji pharmaceutical (000952.SZ): intends to pre-list and transfer 90% equity of its holding subsidiary hubei guangji pharmaceutical technology co., ltd.
On September 20th, Guangji Pharmaceutical (000952.SZ) announced that in order to effectively utilize asset resources and realize asset value, the company plans to transfer 90% equity of its holding subsidiary Hubei Guangji Medical Technology Co., Ltd. through pre-listing transfer on Shanghai United Property Exchange in accordance with relevant regulations on state-owned property rights management. The transfer price will be based on the evaluation results filed after the formal listing transfer and will be determined after the corresponding approval procedures of the company are completed.
Guangji Pharmaceutical: Semi-Annual Report 2024
Guangji Pharmaceutical: 2024 Semi-Annual Report Summary
Hubei Guangji Pharmaceutical (000952.SZ) released its performance for the first half of the year, with a net loss of 107 million yuan.
Hubei Guangji Pharmaceutical (000952.SZ) has released its 2024 interim report, during the reporting period, the company achieved revenue...
Hubei Guangji Pharmaceutical: 2024 Interim Performance Forecast
Guangji Pharmaceutical (000952.SZ): The company uses microbial fermentation to produce vitamin B2
Gelonghui, May 9 | Guangji Pharmaceutical (000952.SZ) said on the investor interactive platform that the company uses microbial fermentation to produce vitamin B2.
Hubei Guangji Pharmaceutical Co., Ltd. (SZSE:000952) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Guangji Pharmaceutical (000952.SZ) announced first-quarter results with a net loss of 50,5082 million
Guangji Pharmaceutical (000952.SZ) released its report for the first quarter of 2024, achieving an operating income of 1.8 during the reporting period...
Guangji Pharmaceutical (000952.SZ): Appoints Lu Zilong as General Manager
Gelonghui, April 12, 丨 Guangji Pharmaceutical (000952.SZ) announced that the company held the 40th (Provisional) Meeting of the 10th Board of Directors on April 12, 2024 to review and pass the “Proposal on Appointing Mr. Lu Zilong as the Company's General Manager”. Following the qualification review by the nomination committee of the 10th board of directors and the approval of the nominees, the board of directors of the company agreed to appoint Mr. Lu Zilong as the general manager of the company. The term of office will begin on the date of review and approval by the board of directors and end on the date of expiration of the 10th board of directors.
Hubei Guangji Pharmaceutical Co., Ltd. (SZSE:000952) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Guangji Pharmaceutical (000952.SZ) appoints Xiong Yi as financial director
Zhitong Finance App News, Guangji Pharmaceutical (000952.SZ) announced that the company's board of directors recently received a written resignation report submitted by the company's director and financial director Hu Mingfeng. Hu Mingfeng applied to resign as the company's financial director due to job changes. After his resignation, Hu Mingfeng continued to serve as the company's director. The company agreed to appoint Xiong Yi as the company's financial director. The term of office will begin on the date of review and approval by the board of directors until the end of the 10th board of directors.
Shareholders in Hubei Guangji Pharmaceutical (SZSE:000952) Have Lost 15%, as Stock Drops 14% This Past Week
Guangji Pharmaceutical (000952.SZ) and related personnel received a warning letter from the Hubei Securities Regulatory Bureau
Guangji Pharmaceutical (000952.SZ) announced that the company recently received from the China Securities Regulatory Commission and the Hubei Regulatory Bureau...
Guangji Pharmaceutical (000952.SZ): Entecavir API marketing application approved
According to the Zhitong Finance App, Guangji Pharmaceutical (000952.SZ) announced that recently, the company received entecavir's “Notice of Approval of Marketing Application for Chemical Raw Materials” issued by the State Drug Administration. According to reports, entecavir is a guanine nucleoside analogue and has an inhibitory effect on hepatitis B virus polymerase. It is suitable for the treatment of chronic adult hepatitis B where virus replication is active, serum alanine aminotransferase (ALT) continues to rise, or liver histology shows active lesions.
[Instant Analysis of BT Financial Report] Guangji Pharmaceutical's 2023 Third Quarter Report: Net Assets Decreased Slightly, Balance Ratio Rise, and Net Profit Turned Negative
Announcement time of this financial report: 2023-10-20 16:03:14 Guangji Pharmaceutical (stock code: 000952) is a pharmaceutical manufacturing enterprise mainly engaged in R&D, production and sales of vitamin B2 and B6 raw material products and pharmaceutical products. The company has established an R&D center with APIs and formulations as the core and a number of supporting subsidiaries, and has developed into a modern pharmaceutical enterprise integrating R&D, production and sales. According to Guangji Pharmaceutical's financial summary for the third quarter of 2023, net assets at the end of the reporting period were 1,483 billion yuan, compared to 1,492 billion yuan at the end of the previous year
No Data
